Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.

You may also be interested in...



FDA Hints At Additional Trials for Acusphere’s Imagify

Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.

FDA Hints At Additional Trials for Acusphere’s Imagify

Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.

CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

A2A-adenosine agonist could see FDA action by mid-March 2008.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel